UnaCom News- An Economic Round Up

                                                                            13th August- 19th August

Astellas buys UK group Quethera

Cambridge based Quethera, a gene therapy group focused on the development of treatments for ocular diseases, has been acquired by Astellas 
As part of the deal, Astellas could pay up to £85 million in aggregate consideration for Quethera, which will then make Quethera a wholly owned subsidiary of Astellas.

Orchard raises $150 million to develop gene therapy pipeline

Orchard Therapeutics has raised $150 million for progression of registration of its three most advanced clinical programmes. The funding will also be used to support development of clinical and pre clinical of Orchards rare disease gene therapy pipeline. 

Novo Nordisk acquires UK group Ziylo

Novo Nordisk has acquired all the shares of Ziylo, a University of Bristol spin out. This deal gives Novo full rights to Ziylo glucose binding molecule platform which has been highlighted as a ‘key strategic area’ in its effort to develop the next generation of insulin. Specific details of the deal have not been revealed, but Novo said it will acquire all shares in Ziylo for an upfront payment and earn outs with contingent milestone payments and that total payments under the deal could overshoot $800 million.

No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...